Zetia, fenofibrate combo OK'd for cholesterol lowering
Merck/Schering-Plough Pharmaceuticals has announced the approval of a new indication for Zetia (ezetimibe). The drug can now be used in combination with fenofibrate, along with diet, for the reduction of high total cholesterol and LDL cholesterol in patients with mixed hyperlipidemia, a metabolic disorder consisting of high LDL cholesterol, low HDL cholesterol, and elevated triglycerides.
Zetia, fenofibrate combo OK'd for cholesterol lowering
Merck/Schering-Plough Pharmaceuticals has announced the approval of a new indication for Zetia (ezetimibe). The drug can now be used in combination with fenofibrate, along with diet, for the reduction of high total cholesterol and LDL cholesterol in patients with mixed hyperlipidemia, a metabolic disorder consisting of high LDL cholesterol, low HDL cholesterol, and elevated triglycerides. Approval was based on a 12-week study that showed that coadministration of the two drugs led to a 20% reduction in LDL cholesterol levels compared with a 6% and 13% reduction with fenofibrate and ezetimibe as monotherapy, respectively.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
